A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
AUTOR(ES)
Yoo, C
FONTE
Nature Publishing Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2778540Documentos Relacionados
- Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P
- Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
- Does second-line therapy affect the radiological progression of rheumatoid arthritis?
- Does second-line therapy affect the radiological progression of rheumatoid arthritis?